Novartis Adds Osteoporosis Claim For Reclast, Plans Prevention Filing By Year End

Novartis plans to file an osteoporosis prevention claim for Reclast (zoledronic acid) by the end of 2007, the company told "The Pink Sheet" after the bisphosphonate's Aug. 17 approval for osteoporosis treatment. The Swiss firm will seek an indication for prevention of clinical fractures after hip fracture in both men and women